세계의 헌팅턴병 치료 시장 분석과 예측 : 치료법(대증요법, 질환 조절 요법), 주요 시장별(2018-2023년)
Huntington´s Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Therapy, Disease-modifying Therapy), By Major Markets, And Segment Forecasts, 2018 - 2023
상품코드 : 726452
리서치사 : Grand View Research, Inc.
발행일 : 2018년 08월
페이지 정보 : 영문 89 Pages
US $ 5,950 ₩ 7,028,000
Unprintable PDF by E-mail (Single User License)
US $ 6,950 ₩ 8,210,000
Printable PDF by E-mail (5-User License)
US $ 8,950 ₩ 10,572,000
Printable PDF by E-mail (Enterprise License)


한글목차

세계의 헌팅턴병 치료(Huntington's Disease Treatment) 시장은 2018-2023년간 38.2%의 CAGR로 추이하며, 2023년까지 15억 달러 규모의 시장으로 성장할 것으로 예측됩니다. 질환 조절 요법의 급속한 보급, 신치료제의 채택 증가, 연구개발 활동의 증가 등에 의해 이 시장의 성장이 촉진되고 있습니다.

세계의 헌팅턴병 치료 시장을 조사했으며, 시장 및 역학의 개요, 시장 동향, 시장 규모의 추이와 예측, 시장 성장요인 및 저해요인 분석, 시장 기회, 파이프라인 정보, 혁신적 치료제의 개요, 시장 점유율, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 조사 방법

제2장 개요

제3장 질환 프라이머와 역학

제4장 세계의 헌팅턴병 치료 시장 개요

제5장 헌팅턴병 치료 시장 : 파이프라인 정보

제6장 기업 개요

제7장 시장 전망

KSA 18.11.08
영문 목차

영문목차

The global huntington's disease treatment market size is expected to be valued at USD 1.5 billion by 2023, as per a new report by Grand View Research, Inc., registering a CAGR of 38.2% during the forecast period. The market is largely driven by factors such as rapid uptake of disease-modifying therapies, increased adoption of novel therapeutics, and increase in R&D activities.

Huntington's disease is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. Currently, only two symptom-alleviating therapies are specifically approved for this disorder: Xenazine and Austedo. Off-label medications are used extensively due to lack of approved alternatives.

The pipeline for Huntington's disease is expected to witness rapid developments in the coming years as disease-modifying drugs transform the market landscape. Improved disease understanding has led to significant progress in the development of therapeutic approaches aimed at modifying specific changes linked to the causative mutation. The potential role of RNA antisense technology and stem cell therapy are under active clinical investigation. Wave Life Sciences and Ionis Pharma's antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.

Further key findings from the report suggest:

Drugs with novel targets in early-phase development include: Stealth Biotherapeutics' SBT-20 (mitochondria-targeted cytoprotective peptide), Cellavita + Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo/ Shire's mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy).

Table of Contents

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Huntington's Disease Treatment Market Overview

Chapter 5 Huntington's Disease Treatment Market: Pipeline Intelligence

Chapter 6 Company Profiles

Chapter 7 Market Outlook

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기